1887

Abstract

Infections due to metallo-beta-lactamase (MBL)-producing organisms are becoming a significant problem, and antibiotic treatment options are limited. Aztreonam inhibits MBLs, and its use in combination with ceftazidime–avibactam (CAZ–AVI–AZT) to inhibit other beta-lactamases shows promise.

A 45-year-old woman suffered from recurrent and sustained MBL (IMP-4)+ complex bacteraemia from an undrainable biliary source, and had failed nine alternative antibiotic regimens over a 5-month period. The 10th episode was successfully treated with CAZ–AVI–AZT, and she has had no further relapses. Three of the isolates underwent whole-genome sequencing (WGS) on the MiSeq platform and were analysed with the Nullarbor pipeline.

A layered Etest method for synergy between CAZ–AVI and aztreonam demonstrated an MIC of 2 mg l for the combination. Isolates were identified by WGS as subsp. . All three of the isolates had TEM-4 ESBL, OXA-1 and ACT-25. Two of the carbapenem-resistant isolates contained IMP-4.

While aztreonam inhibits MBLs, MBL-positive isolates often express other beta-lactamase enzymes. Avibactam inhibits ESBLs and other beta-lactamases, and its use in this case possibly contributed to therapeutic success due to inhibition of the concomitant TEM-4 in the isolates. This case demonstrates that phenotypic antimicrobial susceptibility testing (layered Etests for synergy), backed up by WGS, can produce results that allow tailored antimicrobial therapy in difficult infections. This case adds to the evidence for using CAZ–AVI–AZT in serious MBL infections.

  • This is an open-access article distributed under the terms of the Creative Commons Attribution License. The Microbiology Society waived the open access fees for this article.
Loading

Article metrics loading...

/content/journal/acmi/10.1099/acmi.0.000248
2021-08-06
2024-12-07
Loading full text...

Full text loading...

/deliver/fulltext/acmi/3/8/acmi000248.html?itemId=/content/journal/acmi/10.1099/acmi.0.000248&mimeType=html&fmt=ahah

References

  1. Seemann T, Goncalves da Silva A, Bulach DM, Schultz MB, Kwong JC et al. Nullarbor; 2021 https://github.com/tseemann/nullarbor
  2. Wood DE, Salzberg SL. Kraken: ultrafast metagenomic sequence classification using exact alignments. Genome Biol 2014; 15:R46 [View Article] [PubMed]
    [Google Scholar]
  3. Bankevich A, Nurk S, Antipov D. SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing. J Comput Biol 2012; 19:455–477 [View Article] [PubMed]
    [Google Scholar]
  4. Carattoli A, Zankari E, García-Fernández A. In silico detection and typing of plasmids using PlasmidFinder and plasmid multilocus sequence typing. Antimicrob Agents Chemother (Bethesda) 2014; 58:3895–3903 [View Article]
    [Google Scholar]
  5. Alcock BP, Raphenya RA, Lau TTY, Tsang KK, Bouchard M et al. CARD 2020: antibiotic resistome surveillance with the comprehensive antibiotic resistance database. Nucleic Acids Res 2020; 48:D517–D525 [View Article] [PubMed]
    [Google Scholar]
  6. Abraham S, O’Dea M, Trott DJ. Isolation and plasmid characterization of carbapenemase (IMP-4) producing Salmonella enterica Typhimurium from cats. Sci Rep 2016; 6:35527 [View Article] [PubMed]
    [Google Scholar]
  7. Marshall S, Hujer AM, Rojas LJ. Can ceftazidime-avibactam and aztreonam overcome beta-lactam resistance conferred by metallo-beta-lactamases in Enterobacteriaceae?. Antimicrob Agents Chemother 2017; 61: [PubMed]
    [Google Scholar]
  8. Mojica MF, Ouellette CP, Leber A, Becknell MB, Ardura MI et al. Successful treatment of bloodstream infection due to metallo-β-lactamase-producing Stenotrophomonas maltophilia in a renal transplant patient. Antimicrob Agents Chemother 2016; 60:5130–5134 [View Article] [PubMed]
    [Google Scholar]
  9. Davido B, Fellous L, Lawrence C, Maxime V, Rottman M et al. Ceftazidime-avibactam and aztreonam, an interesting strategy to overcome β-lactam resistance conferred by metallo-β-lactamases in Enterobacteriaceae and Pseudomonas aeruginosa . Antimicrob Agents Chemother 2017; 61: [View Article] [PubMed]
    [Google Scholar]
  10. Falcone MD, Tiseo G, Bassoulis D, Giordano C, Galfo V et al. Efficacy of ceftazidime-avibactam plus aztreonam in patients with bloodstream infections caused by MBL- producing Enterobacterales . Clin Infect Dis 2020
    [Google Scholar]
  11. Davido B, Batista R, Michelon H, Lepainteur M, Bouchand F et al. Is faecal microbiota transplantation an option to eradicate highly drug-resistant enteric bacteria carriage?. J Hosp Infect 2017; 95:433–437 [View Article]
    [Google Scholar]
  12. Mittal J, Szymczak WA, Guo Y. Two for the price of one: emerging carbapenemases in a returning traveller to New York City. BMJ Case Rep 2018; 2018: [View Article] [PubMed]
    [Google Scholar]
  13. Leung GH, Gray TJ, Cheong EY. Persistence of related bla-IMP-4 metallo-beta-lactamase producing Enterobacteriaceae from clinical and environmental specimens within a burns unit in Australia - a six-year retrospective study. Antimicrob Resist Infect Control 2013; 2:35 [View Article] [PubMed]
    [Google Scholar]
  14. Marmor A, Daveson K, Harley D. Two carbapenemase-producing Enterobacteriaceae outbreaks detected retrospectively by whole-genome sequencing at an Australian tertiary hospital. Infect Dis Health 2020; 25:30–33 [View Article] [PubMed]
    [Google Scholar]
  15. Bell JM, Gottlieb T, Daley DA, Coombs GW. Australian Group on Antimicrobial Resistance (AGAR) Australian Gram-negative Sepsis Outcome Programme (GNSOP) Annual Report 2017 Canberra: Australian Government; 2019 pp 1–9
    [Google Scholar]
  16. Roberts LW, Catchpoole E, Jennison AV. Genomic analysis of carbapenemase-producing Enterobacteriaceae in Queensland reveals widespread transmission of blaIMP-4 on an IncHI2 plasmid. Microb Genom 2020; 6: [View Article] [PubMed]
    [Google Scholar]
  17. Kizny Gordon A, Phan HTT, Lipworth SI, Cheong E, Gottlieb T et al. Genomic dynamics of species and mobile genetic elements in a prolonged blaIMP-4-associated carbapenemase outbreak in an Australian hospital. J Antimicrob Chemother 2020; 75:873–882 [View Article]
    [Google Scholar]
/content/journal/acmi/10.1099/acmi.0.000248
Loading
/content/journal/acmi/10.1099/acmi.0.000248
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error